Regulatory Effects of 5-Day Oral and Intraperitoneal Administration of a Thienopyrimidine Derivative on the Thyroid Status in Rats

[helvella]

Why would you want to read this? Well, it suggests a way of treating some hypothyroid issues without affecting the thyroid itself. Very much related to the issues discussed in this very recent post:

How does taking thyroid hormone switch off our own hormone production?

healthunlocked.com/thyroidu...

The substance is, more or less, equivalent to TRH (TSH releasing hormone, also called thyroliberin). If the person isn't producing enough TRH, they won't produce enough TSH, hence will not produce enough thyroid hormone - and they will be hypothyroid.

But if the TRH is replaced/supplemented, the entire rest of the system can function as if there were no issue.

The problems being the substance used, how it can be delivered, how the dose can be managed, and - of course - whether there are other issues caused by adopting this approach.

Obviously this is not a suitable approach if the person doesn't have a working thyroid. So unlikely to help in cases of thyroid cancer, post-thyroidectomy and autoimmune thyroid disease which causes the destruction of the thyroid. But might be extremely valuable to some.

Bull Exp Biol Med. 2024 Sep 12.

doi: 10.1007/s10517-024-06223-8 Online ahead of print.

Regulatory Effects of 5-Day Oral and Intraperitoneal Administration of a Thienopyrimidine Derivative on the Thyroid Status in Rats

K V Derkach 1 , V N Sorokoumov 2 , I Yu Morina 2 , V S Kuznetsova 2 , I V Romanova 2 , A O Shpakov 2

PMID: 39266923 DOI: 10.1007/s10517-024-06223-8

Abstract

In experiments on rats, we studied the effect of 5-day intraperitoneal (15 mg/kg/day) and oral (40 mg/kg/day) administration of compound TPY3m, a stimulator of the production of thyroid hormones by the thyroid gland developed by us, on the blood levels of thyroxine, triiodothyronine, and thyroid-stimulating hormone and on morphology of the thyroid gland. With both routes of administration, TPY3m caused a sustained moderate elevation of thyroid hormones, mainly thyroxine, with little effect on the level of thyroid-stimulating hormone. TPY3m did not reduce the stimulating effect of thyroliberin on the levels of thyroid hormones and had no damaging effect on the thyroid gland. During long-term administration, compound TPY3m stimulates the production of thyroid hormones without weakening the activity of the thyroid axis. Thus, TPY3m is a prototype of drugs for correcting thyroid hormone deficiency.

Keywords: allosteric agonist; hypothyroidism; thyroid gland; thyroid-stimulating hormone receptor; thyroxine.

[linda96]

thank you Helvella, interesting paper. Did you note if they ever would use it in humans at all?

[helvella Administrator in reply to linda96]

I'm sure that is in their plans.

Russian research often doesn't make it to us - and prospects for more research and closer cooperation look bleak at present.

[TSH110 in reply to helvella]

Why do you think they are looking into it?

[helvella Administrator in reply to TSH110]

Because moving from initial animal trials, through to human trials is the usual path. They seem quite excited.

Even if it is not those individuals, research of an actual research drug indicates someone has bothered to produce it, and someone has paid for it to be done. That usually implies an eventual target of its use in human and/or veterinary work in future - if it gets through trials. And then actual use will be dependent on commercial decisions.

[TSH110 in reply to helvella]

Well it is ground breaking stuff if all goes well with trials, so they ought to be chuffed.

Alas of no value to me, even if I lived long enough for it to be used in humans.

[TSH110]

interesting, poor mice - as ever, but a bit more imaginative than the anti t3 and NDT brigade here who seem to think thyroid disorder is licked with their gold standard Levothyroxine and TSH, despite their patients telling them otherwise